– Why Not Eliminate Delays, Costs, and Hassles of Midcourse Corrections? –
FREMONT, Calif., April 23, 2025 /PRNewswire/ — OrthoFX™, a leading innovator in the clear aligner industry, will present its full portfolio of cutting-edge clear aligner products at the American Association of Orthodontists (AAO) 2025 conference in Philadelphia, PA, from April 25 to 27. Among its offerings, Rescue™ aligners—the only treatment recovery aligner in the industry —will take center stage, redefining midcourse corrections by eliminating or reducing unnecessary delays, costs, and disruptions for orthodontic practices and patients.
“Rescue aligners have become an invaluable tool for orthodontic practices, dramatically improving the patient experience without extending treatment duration,” said Ren Menon, OrthoFX Co-founder. “For over two decades, midcourse corrections have been a persistent challenge in orthodontics. With Rescue aligners, patients can remain on track while avoiding additional office visits, digital scans, and repeated aligner deliveries. We’re excited to showcase this innovation and demonstrate how it simplifies treatment for both doctors and patients.”
By using FXOnTrack, an AI-driven remote monitoring solution, off-track treatments are detected, and Rescue aligners are approved by the doctor and shipped directly to the patient in as little as one week. While the traditional midcourse correction process may result in 8+ weeks in treatment delays, requiring the creation of a new treatment plan, and may add up to 20% more aligner stages, Rescue aligners are designed to get the patient back to the original treatment plan in 2-3 weeks without office visits.
OrthoFX will also showcase a range of industry-leading aligner solutions designed to enhance treatment efficiency and patient compliance, including:
“OrthoFX is aware of the challenges that plague a modern practice daily. They have a deep understanding of efficiency with clear aligner therapy and have developed systems that are hyper-focused on delivering efficient care the first time, reducing midcourse corrections. Their unique solution to recapturing cases that go off target, Rescue aligners, is an industry first,” said Dr. Neil Warshawsky, Orthodontist, Professor, and OrthoFX provider. “It is clever, unique, and most importantly, it keeps your patients from rescanning and rebuilding, which takes time and resources, something we are all short of. When you combine this with free remote monitoring, it truly represents the best of the best. With OrthoFX, I work smarter, hit my target routinely, and exceed patient expectations.”
To explore the next generation polymers firsthand, visit the OrthoFX booth #1035 at AAO 2025. For additional information about OrthoFX and its product lineup, visit www.orthofx.com.
About OrthoFX™
OrthoFX™ was founded by pioneers in the clear aligner industry who helped develop and scale leading aligner brands. Recognizing the need for greater treatment predictability and patient compliance, OrthoFX reimagined aligner technology—integrating next-generation polymers, intelligent software, and streamlined services to provide doctors with superior aligner systems and offer patients solutions tailored to their lifestyles.
OrthoFX’s portfolio includes Rescue™, FXClear™, FXBright™, and AirFlex™—all designed for practice efficiency and to fit with patients’ lifestyles.
For more information about how to become an OrthoFX provider, visit www.orthofx.com. Connect on Facebook, Instagram, TikTok and LinkedIn. For media inquiries, please contact Media@OrthoFX.com
* Data on file at OrthoFX
SOURCE OrthoFX
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…